Table 1.
Demographic characteristics of the study cohort
| Characteristic | HC (n=68) |
RRMS (n=151) |
PMS (n=100) |
p value |
|---|---|---|---|---|
| Age (years), mean (SD) | 40.7 (14.5) | 41.3 (10.9) | 52.1 (10.1) | <0.001 a |
|
|
||||
| Female Sex, n (%) | 48 (71%) | 124 (82%) | 63 (63%) | 0.003 b |
|
|
||||
| Race, n (%) | 0.019 c | |||
| Caucasian American | 50 (74%) | 114 (76%) | 83 (83%) | |
| African American | 7 (10%) | 28 (19%) | 14 (14%) | |
| Other | 11 (16%) | 9 (6%) | 3 (3%) | |
|
|
||||
| DMT d | ||||
| None | 14 (9%) | 28 (28%) | ||
| High potency | 56 (37%) | 25 (25%) | ||
| Intermediate potency | 9 (6%) | 4 (4%) | ||
| Low potency | 69 (46%) | 40 (40%) | ||
| Other | 3 (2%) | 3 (3%) | ||
|
|
||||
| EDSS, median (IQR) | 2 (1.5-3.5) | 6 (4-6.5) | <0.001 e | |
|
|
||||
| Disease duration (years), median (IQR) | 8 (4-12) | 13.5 (9-22) | <0.001 e | |
a
One-way ANOVA
b
Chi-square test
c
Fisher’s exact test
d
Glatiramer acetate, interferon-beta, and teriflunomide were classified as low-potency DMTs, dimethyl fumarate and fingolimod as intermediate-potency DMTs, and natalizumab, ocrelizumab, rituximab, alemtuzumab, and daclizumab as high-potency DMTs.
e
Wilcoxon rank-sum test
HC: Healthy Controls; MS: Multiple Sclerosis; RRMS: Relapsing-Remitting MS; PMS: Progressive MS; SD: Standard Deviation; DMT: Disease Modifying Treatment; EDSS: Expanded Disability Status Scale; IQR: Interquartile range